OneOncology’s Oncology Quality Hub was approved by CMS as both a QCDR and a QR in 2024. This designation represents a key OneOncology offering available to its partner practices: the ability to collect clinical data from a variety of sources and report MIPS measures regardless of EMR provider, streamlining practice quality reporting and driving improved performance.

This recognition by CMS reflects OneOncology’s ability to meet rigorous federal standards for collecting and submitting clinical data on behalf of healthcare providers as part of CMS’s Quality Payment Program.

As a QCDR, OneOncology is also now authorized to develop new quality measures that CMS can recognize and incorporate into the MIPS program. By developing new quality measures for CMS consideration, OneOncology is at the forefront of shaping and defining clinical quality metrics in oncology.

For the 2023 reporting period, OneOncology partner practices achieved an average MIPS score of 96, marking a 13 percent improvement year over year. Final MIPS scores for 2023 directly influence payment adjustments for 2025.